Evaluation of Paxillin Expression in Epithelial Dysplasia, Oral Squamous Cell Carcinoma, Lichen Planus with and without Dysplasia, and Hyperkeratosis : A Retrospective Cross-Sectional Study
BACKGROUND: Paxillin is a cytoskeletal protein involved in the pathogenesis of several types of cancers. However, the roles of paxillin in epithelial dysplasia (ED), oral squamous cell carcinoma (OSCC), oral lichen planus with dysplasia (OLPD), hyperkeratosis (HK), and oral lichen planus (OLP) have remained unnoticed in the literature. This study aimed to evaluate its attainable functions in the pathogenesis and malignant transformation of potentially malignant oral epithelium and benign lesions.
METHODS: In this retrospective cross-sectional study, paxillin expression was investigated in 99 tissue samples, including 18 cases of OSCC, 21 ED, 23 OLP, 21 OLPD, and 16 cases of HK. The tissue sections also underwent immunohistochemical paxillin staining using 3,3-diaminobenzidine (DAB) chromogen. The intensity, location, and percentage of staining were examined across all groups. Data were analyzed using the Shapiro-Wilk test, ANOVA, Pearson chi-square, Kruskal-Wallis, and Dunn's post hoc test.
RESULTS: The cytoplasmic percentage and intensity staining of Paxillin expression were evident in the central/suprabasal and basal/peripheral layers of all the obtained samples. The final staining score was significantly higher in OSCC and dysplasia compared to HK and OLP (p = 0.004). It was found that paxillin expression is associated with the grade of dysplastic samples (p < 0.001).
CONCLUSION: The present study provides evidence that paxillin may be involved in the pathogenesis of OSCC and the development and progression of dysplastic tissue, since the paxillin expression was higher than that of HK and OLP.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
---|---|
Enthalten in: |
Diagnostics (Basel, Switzerland) - 13(2023), 15 vom: 25. Juli |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Aghili, Seyedeh Sara [VerfasserIn] |
---|
Links: |
---|
Themen: |
Carcinomatosis |
---|
Anmerkungen: |
Date Revised 14.08.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
---|
doi: |
10.3390/diagnostics13152476 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM360683479 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM360683479 | ||
003 | DE-627 | ||
005 | 20231226083531.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3390/diagnostics13152476 |2 doi | |
028 | 5 | 2 | |a pubmed24n1202.xml |
035 | |a (DE-627)NLM360683479 | ||
035 | |a (NLM)37568839 | ||
035 | |a (PII)2476 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Aghili, Seyedeh Sara |e verfasserin |4 aut | |
245 | 1 | 0 | |a Evaluation of Paxillin Expression in Epithelial Dysplasia, Oral Squamous Cell Carcinoma, Lichen Planus with and without Dysplasia, and Hyperkeratosis |b A Retrospective Cross-Sectional Study |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 14.08.2023 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status PubMed-not-MEDLINE | ||
520 | |a BACKGROUND: Paxillin is a cytoskeletal protein involved in the pathogenesis of several types of cancers. However, the roles of paxillin in epithelial dysplasia (ED), oral squamous cell carcinoma (OSCC), oral lichen planus with dysplasia (OLPD), hyperkeratosis (HK), and oral lichen planus (OLP) have remained unnoticed in the literature. This study aimed to evaluate its attainable functions in the pathogenesis and malignant transformation of potentially malignant oral epithelium and benign lesions | ||
520 | |a METHODS: In this retrospective cross-sectional study, paxillin expression was investigated in 99 tissue samples, including 18 cases of OSCC, 21 ED, 23 OLP, 21 OLPD, and 16 cases of HK. The tissue sections also underwent immunohistochemical paxillin staining using 3,3-diaminobenzidine (DAB) chromogen. The intensity, location, and percentage of staining were examined across all groups. Data were analyzed using the Shapiro-Wilk test, ANOVA, Pearson chi-square, Kruskal-Wallis, and Dunn's post hoc test | ||
520 | |a RESULTS: The cytoplasmic percentage and intensity staining of Paxillin expression were evident in the central/suprabasal and basal/peripheral layers of all the obtained samples. The final staining score was significantly higher in OSCC and dysplasia compared to HK and OLP (p = 0.004). It was found that paxillin expression is associated with the grade of dysplastic samples (p < 0.001) | ||
520 | |a CONCLUSION: The present study provides evidence that paxillin may be involved in the pathogenesis of OSCC and the development and progression of dysplastic tissue, since the paxillin expression was higher than that of HK and OLP | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a carcinomatosis | |
650 | 4 | |a dysplasia | |
650 | 4 | |a lichen planus | |
650 | 4 | |a paxillin | |
650 | 4 | |a squamous cell carcinoma | |
700 | 1 | |a Zare, Razieh |e verfasserin |4 aut | |
700 | 1 | |a Jahangirnia, Alireza |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Diagnostics (Basel, Switzerland) |d 2011 |g 13(2023), 15 vom: 25. Juli |w (DE-627)NLM250111136 |x 2075-4418 |7 nnns |
773 | 1 | 8 | |g volume:13 |g year:2023 |g number:15 |g day:25 |g month:07 |
856 | 4 | 0 | |u http://dx.doi.org/10.3390/diagnostics13152476 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 13 |j 2023 |e 15 |b 25 |c 07 |